{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:05:34Z","timestamp":1784808334131,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"DOI":"10.7759\/cureus.113216","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:47:14Z","timestamp":1784807234000},"source":"Crossref","is-referenced-by-count":0,"title":["Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Lakshya","family":"Motwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Doddapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L","family":"Heuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi A","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, et al.. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022, 20:10.1186\/s12964-022-00854-y","journal-title":"Cell Commun Signal"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang Y","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, et al.. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019, 5:1008-19. 10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic NB","year":"2024","unstructured":"Curkovic NB, Bai K, Ye F, Johnson DB. Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis. Cancers (Basel). 2024, 16:10.3390\/cancers16020340","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, et al.. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018, 79:1081-8. 10.1016\/j.jaad.2018.07.008","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach HT","year":"2021","unstructured":"Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021, 85:956-66. 10.1016\/j.jaad.2020.09.054","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1478318","article-title":"Linear IgA bullous dermatosis - a fifty year experience of Warsaw center of bullous diseases","volume":"15","author":"Kowalewski C","year":"2024","unstructured":"Kowalewski C, Wozniak K. Linear IgA bullous dermatosis - a fifty year experience of Warsaw center of bullous diseases. Front Immunol. 2024, 15:10.3389\/fimmu.2024.1478318","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255716","article-title":"Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis","volume":"16","author":"Garrett NF","year":"2021","unstructured":"Garrett NF, da Costa AC, Ferreira EB, Damiani G, Reis PE, Vasques CI. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis. PLoS One. 2021, 16:10.1371\/journal.pone.0255716","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum VR","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA, et al.. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016, 60:12-25. 10.1016\/j.ejca.2016.02.010","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han Y","year":"2021","unstructured":"Han Y, Wang J, Xu B. Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021, 163:10.1016\/j.critrevonc.2021.103376","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000288","article-title":"Linear IgA disease of the gingiva following nivolumab therapy","volume":"42","author":"Jonna S","year":"2019","unstructured":"Jonna S, Neiders M, Lakshmanan S, et al.. Linear IgA disease of the gingiva following nivolumab therapy. J Immunother. 2019, 42:345-7. 10.1097\/CJI.0000000000000288","journal-title":"J Immunother"},{"key":"ref11","article-title":"Linear immunoglobulin A bullous dermatosis induced by atezolizumab","volume":"16","author":"Almutairi S","year":"2024","unstructured":"Almutairi S, Alessa D. Linear immunoglobulin A bullous dermatosis induced by atezolizumab. Dermatol Reports. 2024, 16:","journal-title":"Dermatol Reports"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21653","article-title":"Atezolizumab-induced linear IgA bullous dermatosis","volume":"187","author":"Aguilar-Duran S","year":"2022","unstructured":"Aguilar-Duran S, Mee J, Popat S, Heelan K. Atezolizumab-induced linear IgA bullous dermatosis. Br J Dermatol. 2022, 187:10.1111\/bjd.21653","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5070\/D329662995","article-title":"Linear IgA bullous dermatosis associated with immunotherapy","volume":"29","author":"Momin B","year":"2023","unstructured":"Momin B, Nguyen TF, Glade D, Messer A. Linear IgA bullous dermatosis associated with immunotherapy. Dermatol Online J. 2023, 29:10.5070\/D329662995","journal-title":"Dermatol Online J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/skinhd\/vzae008","article-title":"Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation","volume":"5","author":"Saeed L","year":"2025","unstructured":"Saeed L, Hosking AM, Grando SA. Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation. Skin Health Dis. 2025, 5:53-5. 10.1093\/skinhd\/vzae008","journal-title":"Skin Health Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1089-2","article-title":"Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients","volume":"14","author":"Genovese G","year":"2019","unstructured":"Genovese G, Venegoni L, Fanoni D, Muratori S, Berti E, Marzano AV. Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients. Orphanet J Rare Dis. 2019, 14:10.1186\/s13023-019-1089-2","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.03.008","article-title":"Linear immunoglobulin A bullous dermatosis","volume":"30","author":"Fortuna G","year":"2012","unstructured":"Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012, 30:38-50. 10.1016\/j.clindermatol.2011.03.008","journal-title":"Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida M","year":"2021","unstructured":"Guida M, Strippoli S, Maule M, et al.. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open. 2021, 6:10.1016\/j.esmoop.2021.100064","journal-title":"ESMO Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5177","article-title":"Autoimmune responses in patients with linear IgA bullous dermatosis: both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule","volume":"102","author":"Lin MS","year":"2002","unstructured":"Lin MS, Fu CL, Olague-Marchan M, Hacker MK, Zillikens D, Giudice GJ, Fairley JA. Autoimmune responses in patients with linear IgA bullous dermatosis: both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule. Clin Immunol. 2002, 102:310-9. 10.1006\/clim.2001.5177","journal-title":"Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503377-linear-iga-bullous-dermatosis-a-rare-immune-related-cutaneous-adverse-event-due-to-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:47:15Z","timestamp":1784807235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503377-linear-iga-bullous-dermatosis-a-rare-immune-related-cutaneous-adverse-event-due-to-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.113216","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}